Literature DB >> 46254

Two distinct chemotactic factor inactivators in human serum.

G Till, P A Ward.   

Abstract

The chemotactic factor inactivator (CFI) has been isolated from whole human serum by a combination of techniques including salt precipitation, anionic exchange, and gel filtration chromatography. Two inactivators have been obtained, a beta-globulin with a sedimentation velocity of approximately 7S and an alpha-globulin with a sedimentation velocity of approximately 4S. The former has a specificity for inactivation of the chemotactic activity associated with the C3 fragments, whereas the C5 chemotactic fragment is specifically inactivated by the alpha-globulin CFI. CFI in crude fractions of human serum is heat labile, time and temperature dependent for its activity, and pH dependent, expressing optimal activity at a pH range of 7.2 to 7.4.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 46254

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  In vitro and in vivo production of chemotactic inhibitors by tumor cells.

Authors:  M C Cohen; J P Brozna; P A Ward
Journal:  Am J Pathol       Date:  1979-03       Impact factor: 4.307

2.  Release of neutrophil chemotactic factors from gastric tissue. Initial biochemical characterization.

Authors:  R A Kozol; R J Downes; D L Kreutzer; S Wentzel; E Rossomando; S A Elgebaly
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

3.  Characterization of the protease activity in the chemotactic factor inactivator.

Authors:  P A Ward; J Ozols
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

4.  Studies on the regulation of the neutrophil chemotactic response using a rapid and reliable method for measuring random migration and chemotaxis of neutrophil granulocytes.

Authors:  H U Keller; H Gerber; M W Hess; H Cottier
Journal:  Agents Actions       Date:  1976-02

5.  The regulation of tissue eosinophil chemotactic factor and inhibitor in allergic skin lesions of Freund's complete adjuvant-treated guinea-pigs.

Authors:  M Hirashima; K Tashiro; H Hayashi
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

6.  Migration of leukocytes under agarose in the presence of some polymers.

Authors:  J Sýkora; A Stajner; V Palisa; V Krigar
Journal:  Folia Microbiol (Praha)       Date:  1982       Impact factor: 2.099

7.  Transient improvement of polymorphonuclear leukocyte function by splenectomy in beta-thalassemia.

Authors:  P E Lianou; H P Bassaris; A T Skoutelis; E G Votta; J T Papavassiliou; J P Phair
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

8.  A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.

Authors:  H D Perez; M Lipton; I M Goldstein
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Serum inhibitor of C5 fragment-mediated polymorphonuclear leukocyte chemotaxis associated with chronic hemodialysis.

Authors:  S E Goldblum; D E Van Epps; W P Reed
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

10.  Serum inhibitory effect on myeloperoxidase in human cancer.

Authors:  B Senelar; R Michel; J Tournamille; H Vannereau; M J Escola; J Taib; A Craste de Paulet
Journal:  Br J Exp Pathol       Date:  1982-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.